Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Mariangela Allocca^{1

2}, María Chaparro³, Haidee Aleman Gonzalez⁴, Marta Maia Bosca-Watts⁵, Carolina Palmela⁶, Ferdinando D'Amico^{2

7}, Eirini Zacharopoulou¹, Uri Kopylov⁸, Pierre Ellul⁹, Giorgos Bamias¹⁰, Vassilios Ntelis¹¹, Adi Lahat⁸, Gerassimos J Mantzaris¹², Ioannis Papaconstantinou¹³, Konstantinos Katsanos¹⁴, Yulia Uspenskaya¹⁵, Dimitrios Christodoulou¹⁴, Shomron Ben Horin⁸, Laurent Peyrin-Biroulet⁷, Joanna Torres⁶, Shaji Sebastian⁴, Javier P Gisbert³, Silvio Danese^{1

2}, Gionata Fiorino²

Affiliations

¹ Humanitas Clinical and Research Center-IRCCS-, via Manzoni 56, 20089 Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
³ Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28001 Madrid, Spain.
⁴ IBD Unit, Hull University Hospitals NHS Trust, Hull HU1, UK.
⁵ IBD Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, 46010 València, Spain.
⁶ Division of Gastroenterology, Hospital Beatriz Ângelo, 2620 Loures, Portugal.
⁷ Department of Gastroenterology, Inserm U1256 NGERE, Nancy University Hospital, Lorraine University, 54500 Vandoeuvre-les-Nancy, France.
⁸ Department of Gastroenterology, Sheba Medical Center, Ramat Gan and Sackler School of Medicine, Tel Aviv University, Jaffa 59623, Israel.
⁹ Division of Gastroenterology, Mater Dei Hospital, MT-34 Msida, Malta.
¹⁰ GI-Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, Medical School, National and Kapodistrian University of Athens, 210 Athens, Greece.
¹¹ G.Gennimatas General Hospital, 210 Athens, Greece.
¹² Department of Gastroenterology, GHA Evaggelismos-Ophthalmiatreion Athinon-Polykliniki, 210 Athens, Greece.
¹³ 2nd Academic Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 210 Athens, Greece.
¹⁴ Division of Gastroenterology, University Hospital and University of Ioannina, 440 Ioannina, Greece.
¹⁵ Medical Center "Ne Bolit" LTT, Leninsky Prospect, 66 Moscow, Russia.

PMID: 33142843
PMCID: PMC7693947
DOI: 10.3390/jcm9113533

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Mariangela Allocca et al. J Clin Med. 2020.

. 2020 Oct 31;9(11):3533.

doi: 10.3390/jcm9113533.

Authors

Affiliations

¹ Humanitas Clinical and Research Center-IRCCS-, via Manzoni 56, 20089 Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
³ Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28001 Madrid, Spain.
⁴ IBD Unit, Hull University Hospitals NHS Trust, Hull HU1, UK.
⁵ IBD Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, 46010 València, Spain.
⁶ Division of Gastroenterology, Hospital Beatriz Ângelo, 2620 Loures, Portugal.
⁷ Department of Gastroenterology, Inserm U1256 NGERE, Nancy University Hospital, Lorraine University, 54500 Vandoeuvre-les-Nancy, France.
⁸ Department of Gastroenterology, Sheba Medical Center, Ramat Gan and Sackler School of Medicine, Tel Aviv University, Jaffa 59623, Israel.
⁹ Division of Gastroenterology, Mater Dei Hospital, MT-34 Msida, Malta.
¹⁰ GI-Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, Medical School, National and Kapodistrian University of Athens, 210 Athens, Greece.
¹¹ G.Gennimatas General Hospital, 210 Athens, Greece.
¹² Department of Gastroenterology, GHA Evaggelismos-Ophthalmiatreion Athinon-Polykliniki, 210 Athens, Greece.
¹³ 2nd Academic Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 210 Athens, Greece.
¹⁴ Division of Gastroenterology, University Hospital and University of Ioannina, 440 Ioannina, Greece.
¹⁵ Medical Center "Ne Bolit" LTT, Leninsky Prospect, 66 Moscow, Russia.

PMID: 33142843
PMCID: PMC7693947
DOI: 10.3390/jcm9113533

Abstract

The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18-62.60; OR 5.1, 95% CI 1.10-23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48-40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04-0.52; OR 0.3, 95% CI 0.10-0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.

Keywords: COVID-19; drugs; immunosuppression; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

M.A. received consulting fees from Nikkiso Europe and lecture fees from Janssen, Abbvie and Pfizer; M.C. has served as a speaker or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma; H.A.G. has received lecture fees from Falk Pharma, Pfizer, Takeda, and Nestle; M.B.W. declares educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, Biogen and Takeda; U.K. received speaker and advisory fees from ABBVIE, Jannsen, MSD, Takeda, Medtronic. Research support, Jannsen, Takeda, Medtronic; G.B. has received advisory and/or speaker fees and/or research support from AbbVie, Celgene, Ferrirng, Genesis, Janssen, MSD, Mylan, Pfizer, Takeda, Galenica; G.J.M. has received advisory and/or speaker fees and/or research support from AbbVie, Celgene, Celtrion, Ferrirng, Genesis, Hospira, Janssen, Millennium Pharmaceuticals, MSD, Mylan, Pharmacosmos, Pfizer, Takeda, VIANEX, Angelini, Falk Pharma, Galenica, Omega Pharma, Menarini Group, Pharmathen; S.B.H. received advisory and/or research support from Abbvie, MSD, Janssen, Celltrion, Takeda, GSK, Pfizer; L.P.B. reports personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; grants from Abbvie, MSD, Takeda; stock options: CTMA; S.S. holds research grants from Biogen, Takeda, AbbVie, Tillotts Pharma, Ferring and Biohit; served on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene and Tillots Pharma; and has received speaker fees from AbbVie, Biogen, AbbVie, Janssen, Merck, Warner Chilcott and Falk Pharma; J.P.G. has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Sandoz, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma; S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor, and Johnson and Johnson; G.F. received consultancy fees from Ferring, MSD, AbbVie, Takeda, Janssen, Amgen, Sandoz, Samsung Bioepis, Celltrion; the other authors have no conflicts to disclose.

Figures

**Figure 1**
Graphical representation of the rate of infected subjects during and outside the lockdown for each country.

**Figure 2**
Graphical representation of the cumulative incidence of COVID-positive patients with IBD in our cohort and in the general population, overall and by country.

See this image and copyright information in PMC

References

1. John Hopkins University Coronavirus Resource Center Coronavirus Covid-19 Global Cases. [(accessed on 25 October 2020)]; Available online: https://coronavirus.jhu.edu/map.html.
1. Boruchowicz A., Duclos B., Soulé J.C., Lerebours E., Lémann M., Belaïche J., Colombel J.F., Cosnes J., Gendre J.P., Carbonnel F. Intravenous cyclosporine in attacks of ulcerative colitis. Dig. Dis. Sci. 1996;41:2471–2476. doi: 10.1007/bf02100145. - DOI - PubMed
1. Panaccione R., Löfberg R., Rutgeerts P., Sandborn W.J., Schreiber S., Berg S., Maa J.-F., Petersson J., Robinson A.M., Colombel J.-F. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies. J. Crohn’s Colitis. 2019;13:725–734. doi: 10.1093/ecco-jcc/jjy223. - DOI - PMC - PubMed
1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
1. Kirchgesner J., Lemaitre M., Carrat F., Zureik M., Carbonnel F., Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155:337–346. doi: 10.1053/j.gastro.2018.04.012. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Affiliations

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Miscellaneous